Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
205.00
+1.68 (+0.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
February 14, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Biogen (BIIB) Q4 2023 Earnings Call Transcript
February 13, 2024
BIIB earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?
February 13, 2024
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Breaking Down Biogen: 8 Analysts Share Their Views
February 13, 2024
Via
Benzinga
Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit
February 13, 2024
The company missed both sales and earnings expectations for the fourth quarter.
Via
Investor's Business Daily
Looking At Biogen's Recent Unusual Options Activity
February 12, 2024
Via
Benzinga
Why Is Biogen Stock Trading Lower On Tuesday?
February 13, 2024
Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs.
Via
Benzinga
Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch
February 13, 2024
Despite the Fed rhetoric about the inflation fight being still on, the central bank will likely cut rates this year, an analyst said.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024
From
Biogen Inc.
Via
GlobeNewswire
Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years
February 09, 2024
Via
Benzinga
Critical Insights From Biogen Analyst Ratings: What You Need To Know
January 24, 2024
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,100 Today
January 11, 2024
Via
Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
Via
Benzinga
Comparing Biogen With Industry Competitors In Biotechnology Industry
January 10, 2024
Via
Benzinga
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
February 12, 2024
For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks.
Via
InvestorPlace
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.
Via
Benzinga
Exposures
Product Safety
Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024
From
Biogen Inc.
Via
GlobeNewswire
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
January 29, 2024
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and...
Via
Benzinga
AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
January 25, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
January 24, 2024
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.
Via
Benzinga
Highlights From the 2024 JPMorgan Health Care Conference
January 22, 2024
Weight loss drugs are taking center spotlight, but other developing treatments could change how we live.
Via
The Motley Fool
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street
January 18, 2024
Nice gains could be on the way for three stocks if analysts are right.
Via
The Motley Fool
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
January 12, 2024
A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection.
Via
Benzinga
Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments
January 10, 2024
Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million.
Via
Benzinga
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
January 03, 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.
Via
The Motley Fool
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
January 02, 2024
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today.
Via
InvestorPlace
Government-granted Patent Monopolies Are Not The Free Market
December 29, 2023
Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -...
Via
Talk Markets
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.